科学研究
报告题目：Consequences of Disclosing Clinical Trial Results: Evidence from the Food and Drug Administration Amendments Act
报告人：王胤
报告时间：2025年3月14日（周五）8:30-10:00
报告地点：#腾讯会议：290-509-764
主办单位：东北财经大学会计学院 辽宁省资本市场财务与会计研究生创新与学术交流中心
【报告摘要】
We examine how the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007, which requires additional disclosures regarding clinical trial results, impacts information asymmetry between the disclosing pharmaceutical firm and capital market participants, the general public, academics, and practitioners. We document a reduction in information asymmetry in capital markets. We also document an increase in adverse event and product problem complaint reports filed against the pharmaceutical firms to the FDA and a higher number of drug and medical device recalls for affected firms after the FDAAA enactment. Finally, cross-sectional analyses suggest that the increase in FDA complaint reports and recalls after the FDAAA enactment was more prominent in firms with a higher bid-ask spread decrease. Taken together, our results suggest that the FDAAA has some benefits for both investors and consumers.
【报告人简介】
王胤，新加坡管理大学会计学助理教授，获巴黎高等商学院管理科学（会计学）博士学位，作为访问学者在密歇根大学罗斯商学院进行学术交流，并曾在法国巴黎银行资产管理控制部门担任经理，负责领导团队进行租赁融资和金融业务的风险管理与财务控制工作。他的研究兴趣涵盖信息披露、资本市场中的广告溢出效应、金融中介、共同所有权、ESG、内幕交易、盈余管理以及监管与公司治理等领域。他的部分研究成果发表在会计学领域期刊The Accounting Review。他还多次获得美国会计学会（AAA）FARS中期会议最佳评审奖，并受邀为多个学术会议与期刊担任审稿人。
【特别提醒】
未经论文作者和主办方允许，严禁将讲座内容录制并公开传播，违者将有可能被追究法律责任。
